News Column

United States : BIOTECHNOLOGY company collaborates to develop medications for autoimmune

June 16, 2014

A US-headquartered biotechnology company, Kineta, and Seattle Children's Research Institute launched the Alliance for Children's Therapeutics, a pediatric funding and research collaboration designed to speed up the development of new medications for teens and children with lupus nephritis and other autoimmune diseases like multiple sclerosis, rheumatoid arthritis and Type 1 diabetes.

The company said that ACT makes a new funding model to accelerate research for its potential use by pediatric patients.

Jim Hendricks, Seattle Children's Research Institute president said financing for pediatric research lags disproportionately behind research funding for adult diseases.

Hendricks said, "30% of the U.S. population is under the age of 21, and yet only 6% of the entire National Institutes of Health's budget is devoted to pediatric medicine and care. This gap results in limited development of new therapies for children, who now often have no other choice than to use adult-only tested medications." 

The company said that there are barriers in developing pediatric therapies and the lack of pediatric medication use information poses risks to teens and children.

The US Food and Drug Administration in 2013 approved 27 new drugs out of which only seven new drugs were approved for pediatric use that same year.

ACT brings together one of the US's top five pediatric research institutions with a leading biotechnology firm. The goal is to speed up development of medicines for teens and children with autoimmune diseases.

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: TendersInfo (India)

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters